

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DARATUMUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Daratumumab Injection (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product, a human monoclonal IgG1 antibody binding to ADP-ribosyl cyclase (CD38), is a biosimilar to the originator drug Darzalex® and has been submitted for clinical trial application as a Class 3.3 therapeutic biological product, for the treatment of adult patients with multiple myeloma.

The Product was developed in accordance with the relevant research guidelines for biosimilars. Pharmaceutical and non-clinical study results indicated that the Product was highly similar to the original reference drug in terms of quality, safety and efficacy, supporting the initiation of subsequent clinical studies.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 23 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.